Pakistan Drug Makers Subject To License Review After DRAP Created
This article was originally published in PharmAsia News
Executive Summary
Drug makers in Pakistan are to be subjected to re-evaluations of their production licenses and renewals as a result of the Drug Regulatory Agency of Pakistan Ordinance.